🔗 Share this article

While the United States undertakes sweeping revisions to its immunization guidelines, one figure has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccines in the pandemic and has focused upon possible deaths after COVID-19 immunization in her brief time at the Food and Drug Administration.

Proposed Changes to Pediatric Immunization Schedule

Public health authorities were set to announce sweeping revisions to the childhood immunization program earlier this month, aligning the US with Denmark’s national calendar, it is understood – a significant shift that would put the US out of step with many the global community with little proof for public health gain. This reveal has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the office this calendar year.

A Shift at the Regulatory Body

This interim role could signify a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon reevaluating already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting certain childhood vaccine recommendations in the US so as to align more like Denmark, a country with universal health coverage and a citizenry approximately the population of Wisconsin’s.

So far comments, she has continued to focus on vaccination policy – traditionally the domain of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Expertise

The appointee has no apparent background in pharmaceutical research, approval processes or administrative roles, which has been typical for past leaders of the CBER. She has worked at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in leading a major agency. She has no expertise in pharmaceutical oversight.”

Past heads of CBER would “understand laws and regulations and the science of drug development”, commented a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that prior appointees who ran the center have had.”

This division has an vast range of responsibilities at the FDA, she emphasized.

“Many people just focuses on the innovative therapies, but the generic drug division clears numerous generic drugs. There is also a biosimilars division, OTC medication office and other areas, and every single one have to be looked after,” Dr. Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major management component to the position, which manages in excess of 5,000 personnel. “It’s a massive administrative position, if you perform it correctly,” the former official said.

Response and Contentious Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this selection signifies more teamwork among agency officials on immunizations, a spokesperson said that the “questions stem from flawed premises”.

“Her resume aligns with the functions of her job,” the spokesperson said, citing the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the agency head's new fast-track approval initiative, a controversial one-day drug-approval program that apparently concerned her preceding directors. “By what process are these therapies being selected for this expedited pathway? Who takes the decisions?” Howard questioned. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards laxer rules of most medications, with the exception of immunizations.”

Public Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, track record, some experts have noted. She released a study using unconfirmed crowd-sourced reports to determine the incidence of myocarditis following COVID-19 immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the current administration included changing rules for novel immunizations and ending “non-essential” vaccines, she remarked after the election on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of excluding adolescent males from getting Covid vaccines.

“She’s an complete ideologue who begins with her beliefs and reverse-engineers to fit the data in a extremely disingenuous, fraudulent way,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|